Circulating Immune Complex, C3 fragments
Also known as: CIC-C3
Use
Many autoimmune disorders, chronic infections, and malignancies are associated with circulating immune complexes. Quantitation of immune complexes assists in staging immunologic disorders. Detection of circulating immune complexes is not essential to any specific diagnosis. Circulating immune complexes may be found without any evident pathology, and positive results do not necessarily implicate immune complex-related disease process.
Special Instructions
For best results, the serum should be separated from the cells within 30 minutes after clotting and then frozen immediately. If ordered together with a C1q Binding Assay, ensure to transfer two 1 mL aliquots of serum into separate tubes for submission.
Limitations
Values between 15 and 20 ug Eq/mL are considered equivocal for the Circulating Immune Complex, C3 fragments assay. A repeat test using a new specimen is recommended, if clinically indicated. Detection of circulating immune complexes is not definitive for any specific disease process.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 5228-2
Result Turnaround Time
2-9 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plain red or serum separator tube (SST)
Collection Instructions
Allow complete clotting of red blood cells (up to 1 hour), then separate serum from cells within 30 minutes and freeze immediately. Transport separate specimens when multiple tests are ordered.
Storage Instructions
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Causes for Rejection
Non-frozen specimens. Specimens exposed to repeated freeze/thaw cycles. Grossly hemolyzed, lipemic, and icteric specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | Unacceptable |
| Frozen | 20 days |